YZYBIO-B: Articles of Association
YZYBIO-B: POLL RESULTS OF THE ANNUAL GENERAL MEETINGHELD ON THURSDAY, JUNE 27, 2024
YZYBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
YZYBIO-B: FORM OF PROXY FOR THE ANNUAL GENERAL MEETING OF 2023
YZYBIO-B: NOTICE OF THE ANNUAL GENERAL MEETING OF 2023
YZYBIO-B: CIRCULAR FOR THE ANNUAL GENERAL MEETING OF 2023
YZYBIO-B: PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
YZYBIO-B: PROPOSED ADOPTION OF THE 2024 H SHARE OPTION PLAN
YZYBIO-B: VOLUNTARY ANNOUNCEMENT - PHASE II STUDY DATA OF M701 FOR THE TREATMENT OFMALIGNANT ASCITES PRESENTED AT THE 2024 ASCO MEETING
YZYBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
YZYBIO-B: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
YZYBIO-B: RESIGNATION OF NON-EXECUTIVE DIRECTOR
YZYBIO-B: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
YZYBIO-B: 2023 ANNUAL REPORT
YZYBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
YZYBIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2023
YZYBIO-B: VOLUNTARY ANNOUNCEMENT -THE FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OFM701, A BISPECIFIC ANTIBODY FOR TREATMENT OF MALIGNANTASCITES
YZYBIO-B: VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT ENROLLED IN PHASE II CLINICALTRIAL OF M701, A BISPECIFIC ANTIBODY FOR TREATMENT OFMALIGNANT PLEURAL EFFUSION
YZYBIO-B: Date of Board Meeting
YZYBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
No Data